Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 530

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • cardiac
  • Medical
  • Device
  • Coating
  • Stent
  • Cancer
  • Ophthalmological
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 530

License Grant
Licensor will grant Licensee an exclusive (even as to Licensor), worldwide, fully-paid, perpetual license (with the right to sublicense) under Licensor’s interest in any Collaboration Technology jointly owned by Licensor and Licensee necessary or useful to make, have made, import, use, offer for sale and sell Development Candidates (and corresponding Collaboration Products), subject to Article 15, for indications other than those which Licensor retains rights hereunder, and products other than Collaboration Products.
License Property
Collaboration Products refer to research, develop and commercialize gene-based products incorporating the VEGF gene for the treatment of coronary artery disease and peripheral vascular disease.  VEGF is a protein that stimulates the formation of new blood vessels and improves blood flow.
Field of Use
Field shall mean the research, drug discovery and development collaboration aimed at therapeutic agents useful for Gene Therapy-based induction of angiogenesis and for the first two years of the Research Program shall include all clinical indications; provided, thereafter the Field shall be limited to the treatment of coronary artery disease (CAD) and/or peripheral vascular disease (PVD) and/or those other specific clinical indications selected by Licensor pursuant to Section 2.5 below.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 299236

License Grant
Under the initial agreement, the Canadian Licensor agreed to license on a co-exclusive certain patent rights, license rights, and technology.

This agreement is extending Licensee’s worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Licensor Technology in the Peripheral Vascular Field of Use and the GI Field of Use.

Licensor newly grants its licensee, the right for Licensee to have third party Distributors distribute Eligible Peripheral Vascular and/or GI Products.

This agreement is co-exclusive with an option to become exclusive.

License Property
This agreement is for paclitaxel or certain other agents as a coating for certain medical devices.

The license agreement regards paclitaxel-eluting stent products and related technologies.  Paclitaxel is released from the balloon or stent to prevent scar tissue formation in the blood vessel that can re-obstruct the artery (restenosis).

Field of Use
As used herein, the Coronary Vascular Field of Use means endoluminal vascular Licensed Applications for the treatment and/or prevention of disease of the coronary arteries and their branches, or other vasculature providing blood flow to the heart.

As used herein, the Peripheral Vascular Field of Use means the endoluminal vascular licensed applications for the treatment or preventionof disease of the peripheral blood vessels of the body.  Notwithstanding the foregoing, Peripheral Vascular Field of Use excludes any application in the Coronary Vascular Field of Use.  

GI Field of Use means the endoluminal licensed applications for the treatment or prevention of disease of the alimentary tract or liver.

IPSCIO Record ID: 2700

License Grant
The two parties entered into a Collaboration Agreement on the development and commercialization of the VEGF Trap in all countries other than Japan, where one party retained the exclusive right to develop and commercialize the VEGF Trap. In January 2005, the parties amended the collaboration Agreement to exclude from the scope of the collaboration the development and commercialization of the VEGF Trap for intraocular delivery to the eye. In December 2005, the parties amended the collaboration Agreement to expand the territory in which the companies are collaborating on the development of the VEGF Trap to include Japan. Under the collaboration Agreement, as amended, the parties will share co-promotion rights and profits on sales, if any, of the VEGF Trap outside of Japan for disease indications included in our collaboration. In Japan, one party is entitled to a royalty on annual sales of the VEGF Trap, subject to certain potential adjustments.
License Property
Under the collaboration Agreement, as amended, agreed upon worldwide development expenses incurred by both companies during the term of the Agreement will be funded by one party. If the collaboration becomes profitable, one party will be obligated to reimburse the other party for 50% of the VEGF Trap development expenses in accordance with a formula based on the amount of development expenses and our share of the collaboration profits and Japan royalties, or at a faster rate at our option.

The VEGF Trap is a protein-based product candidate designed to bind all forms of Vascular Endothelial Growth Factor-A (called VEGF-A, also known as Vascular Permeability Factor or VPF) and the related Placental Growth Factor (called PlGF), and prevent their interaction with cell surface receptors. VEGF-A (and to a less validated degree, PlGF) is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage.

The VEGF Trap (aflibercept) is being developed in cancer indications in collaboration with another party. We and the other party are preparing to initiate a large Phase 3 program that will evaluate the safety and efficacy of the VEGF Trap in combination with standard chemotherapy regimens in five different cancer types. The first trial is planned to begin in the third quarter of 2007.

Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 280643

License Grant
The Parties have an agreement to develop technology useful for in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

For the RHOA Target, pursuant to the terms of the Original Agreement, Licensor selected the RHOA Target for the development of RNAi Products directed toward such Target (RHOA Products) and Licensee has an opt-in right for further development and commercialization of RHOA Products.

For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.

For the Profit-Sharing Products:
For Development Licenses, Licensor grants a worldwide license in the Territory, with a right to sublicense to its Affiliates, under Licensor Target Identification and Target Validation RNAi Patent Rights, under Licensors interest in Joint Collaboration Patent Rights and Joint Collaboration Inventions, under Licensor Technology Collaboration Inventions, to Licensor RNAi Technology and under Licensor-Assigned Therapeutic Collaboration Inventions, for the sole purpose of in vitro and/or in vivo target identification and/or target validation research relating to drug discovery and/or development activities of Licensee and/or its Affiliates, including in collaborations with Third Parties in which Licensee and/or its Affiliates has any rights to discoveries made.

For Commercialization Licenses,  Licensor grants a license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the Territory.

The foregoing license shall be Exclusive, Co-exclusive or Non-exclusive, depending upon the time period.

License Property
The developed technology will relate to in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.

Field of Use
The Field shall mean the treatment and/or prophylaxis of diseases in humans with RNAi Therapeutic Products.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF),[1] is a signal protein produced by cells that stimulates the formation of blood vessels.  To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors.

IPSCIO Record ID: 255948

License Grant
This Agreement is for the Transfer and assign from Licensor to Licensee for all right, title, and interest to the patent and related clinical information covering LiprostinTM.
License Property
The pharmaceutical drug candidate is LiprostinTM for improving the effectiveness of current standard-of-care treatments related to endovascular interventions in the treatment of peripheral artery disease (PAD). LiprostinTM has completed FDA Phase I and three Phase II clinical trials, and we are evaluating several contract research organizations ('CRO') for completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase III.
Field of Use
The clinical stage patented pharmaceutical brand LiprostinTM is focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).
Peripheral artery disease is a narrowing of the peripheral arteries serving the legs, stomach, arms and head. (“Peripheral” in this case means away from the heart, in the outer regions of the body.) PAD most commonly affects arteries in the legs. Both PAD and coronary artery disease (CAD) are caused by atherosclerosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.